SHigh-throughput Screening
Genetic and small-molecule screens — including CRISPR-based functional genomics — to find combination strategies, resistance mechanisms, and novel targets in PDAC.
What We Do
Research Programs
Five interconnected pillars — the sPARK acronym — driving translational breakthroughs in pancreatic ductal adenocarcinoma (PDAC), now extending across gastrointestinal cancers through GRIT (GI RAS Innovative Therapeutics).
PPathology AI
AI-enabled pathology and multimodal data integration to connect tissue phenotypes with therapeutic vulnerabilities in PDAC.
ANeoantigens & Biologics
Pipelines for neoantigen discovery and biologic modalities targeting tumor-specific epitopes.
RDNA Damage Repair & PARP-Immunotherapy
Combining DNA-damage-repair targeting with immunotherapy in BRCA/PALB2-mutated and HRD pancreatic cancer.
Nature Medicine 2026
KKRAS-driven Vulnerabilities
Targeting KRAS G12D — the most common variant in PDAC — with first-in-class degraders and RAS(ON) inhibitors.
NEJM 2026
GRIT — GI RAS Innovative Therapeutics
A cross-tumor initiative extending RAS-directed precision therapy across gastrointestinal cancers — from pancreatic cancer to biliary tract, gastric/GEJ, appendiceal, and colorectal cancer.
Initiative
Biliary Tract Cancer
Extending our KRAS/RAS and precision-oncology work into biliary tract cancer — genomic determinants of chemotherapy benefit today, and RAS-directed trials next.
New · 2026